MARKET

AKBA

AKBA

Akebia Therapeut
NASDAQ
1.340
+0.010
+0.75%
After Hours: 1.330 -0.01 -0.72% 19:10 04/26 EDT
OPEN
1.320
PREV CLOSE
1.330
HIGH
1.350
LOW
1.290
VOLUME
2.48M
TURNOVER
0
52 WEEK HIGH
2.480
52 WEEK LOW
0.6500
MARKET CAP
280.56M
P/E (TTM)
-4.8375
1D
5D
1M
3M
1Y
5Y
Piper Sandler Sticks to Its Buy Rating for Akebia Therapeutics (AKBA)
TipRanks · 1d ago
Weekly Report: what happened at AKBA last week (0415-0419)?
Weekly Report · 5d ago
AKEBIA THERAPEUTICS INC: ON APRIL 15, COMPANY AND STA ENTERED INTO AMENDMENT #2 TO SUPPLY AGREEMENT
Reuters · 04/16 11:35
Weekly Report: what happened at AKBA last week (0408-0412)?
Weekly Report · 04/15 10:36
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
IN8bio stock increased by 47.7% to $1.61 during Wednesday's pre-market session. Jaguar Health (NASDAQ:JAGX) shares rose 25.0% during the session. China SXT Pharmaceuticals shares moved upwards by 24.85%. Losers in the market were BioSig Technologies and Kineta.
Benzinga · 04/10 12:09
Weekly Report: what happened at AKBA last week (0401-0405)?
Weekly Report · 04/08 10:39
Buy Vafseo's Approval: A New Chapter For Akebia Therapeutics In Anemia Management
Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis in March 2024. The company's other FDA-approved drug, Auryxia, will face generic competition in March 2025. Akebia is a biopharmaceutical company specializing in anemia management due to chronic kidney disease. Its drug, VafSEo, is expected to become the company's main revenue driver. I lean towards a cautious "Buy" for Akebia.
Seeking Alpha · 04/04 21:56
Akebia's Vafseo Faces Grim Market Outlook (Rating Downgrade)
Akebia's Vafseo, a HIF-PH inhibitor for DD-CKD anemia, faces skepticism despite FDA approval due to safety concerns. The drug was approved in March for adults with dialysis-dependent chronic kidney disease. GSK's Jesduvroq was approved for the same indication last year. Akebia's financials show modest net income and a shrinking cash reserve.
Seeking Alpha · 04/02 10:16
More
About AKBA
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company is focused on developing and commercializing therapeutics. The Company’s portfolio and hypoxia-inducible factor (HIF)-based pipeline includes Auryxia (ferric citrate), Vafseo (vadadustat), AKB-9090 and AKB-10108. Auryxia (ferric citrate) is an orally administered medicine approved and marketed in the United States for two indications: the control of serum phosphorus levels in adult patients with dialysis dependent chronic kidney disease (DD-CKD), and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis-dependent chronic kidney disease (NDD-CKD). Vafseo (vadadustat) is a HIF prolyl hydroxylase (HIF-PH), inhibitor, approved in 36 countries as a treatment for anemia due to chronic kidney disease (CKD). It utilizes third parties for the commercial distribution of Auryxia, including wholesale distributors and certain specialty pharmacy providers.

Webull offers Akebia Therapeutics Inc stock information, including NASDAQ: AKBA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AKBA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AKBA stock methods without spending real money on the virtual paper trading platform.